Dr. McCulloch on the Likelihood of Relapse on a BTK Inhibitor in MCL

Rory McCulloch, MD
Published: Wednesday, Sep 04, 2019



Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the likelihood of relapse on a BTK inhibitor in mantle cell lymphoma (MCL).

BTK inhibitors have revolutionized the treatment landscape of MCL, but the data show that approximately half of patients will not have a durable response. Ultimately, every patient will end up relapsing at some point, says McCulloch. The field is reaching the stage where the majority of patients have been exposed to a BTK inhibitor and are at the point of relapse. The question now is what to do next.

Early data have shown that it is a very difficult point in the treatment algorithm and there have been no satisfactory treatments that have surfaced, says McCulloch. The average response rate is typically about 30%. Moreover, the progression-free survival, in the best study, which was with venetoclax (Venclexta), is only about 3 months. This reflects a large unmet need, which investigators are hoping to fill with novel regimens.
SELECTED
LANGUAGE


Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the likelihood of relapse on a BTK inhibitor in mantle cell lymphoma (MCL).

BTK inhibitors have revolutionized the treatment landscape of MCL, but the data show that approximately half of patients will not have a durable response. Ultimately, every patient will end up relapsing at some point, says McCulloch. The field is reaching the stage where the majority of patients have been exposed to a BTK inhibitor and are at the point of relapse. The question now is what to do next.

Early data have shown that it is a very difficult point in the treatment algorithm and there have been no satisfactory treatments that have surfaced, says McCulloch. The average response rate is typically about 30%. Moreover, the progression-free survival, in the best study, which was with venetoclax (Venclexta), is only about 3 months. This reflects a large unmet need, which investigators are hoping to fill with novel regimens.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x